Screening Target definition

Screening Target means a Target agreed to by the Parties pursuant to Section 2.1.2.
Sample 1Sample 2Sample 3
Screening Target means a specific protein target - selected by Aventis for which NeoGenesis will perform the Program and for which the screening fee described in Section 4.1, the success payment described in Section 4.4, the milestone payments described in Section 4.5 and royalties described in Section 4.6 are due from Aventis to NeoGenesis as specified in Section 4. An Excluded Target is not a Screening Target for purposes of this Agreement until such time as it becomes a Screening Target. The initial Screening Targets are identified in ATTACHMENT C. TERRITORY means all the countries of the world.
Sample 1
Screening Target means an Accepted Target selected by LG Chem pursuant to Section 4.3;
Sample 1

Examples of Screening Target in a sentence

  • Refer to Screening Target Chemicals of Concern from PCL Development (RG-366/TRRP-14).

  • During the initial validation process (i.e. the comparison test if not already determined in the manufacturer’s R&D programme), the Cut-Off Level may be established through analysis of matrix blank samples and replicates of those same samples spiked (fortified) at the Screening Target Concentration.

  • Cut-off LevelThe Cut-Off Level is the response or signal from a screening test which indicates that a sample contains a substance at or above the Screening Target Concentration.

  • Refer to the TRRP rule (§350.71(k)) and the guidance in Screening Target Chemicals of Concern from PCL Development (RG-366/TRRP-14) for instructions on how to screen COCs.Table 10A.

  • The screening criteria are specified in §350.71(k) and are discussed in detail in TCEQ guidance document Screening Target COCs from PCL Development (RG- 366/TRRP-14).The main emphasis of this guidance will be on the “information-based” approach wherein target COCs may be designated based on appropriate information without prior analyses being performed.

  • The lower the Screening Target Concentration in comparison with the Regulatory Limit, the fewer replicates are required to give the same degree of confidence that the screening test will correctly identify truly contaminated samples at the Regulatory Limit.

  • However, the extent of validation required will vary depending on whether the validation is initial or abridged.Minimum performance parameters for screening tests are specified in Chapter 3, Table 9 of Commission Decision 2002/657/EC [1].As a general principle, there has to be a sufficient margin of difference between the Screening Target Concentration and the Regulatory Limit.

  • By that, we mean that we can read it any base64 encoded string back into a UTF-8 encoded string, and then we can convert this UTF-8 encoded string back into an array of 8-bit unsigned integers while entirely preserving the contents and size of the array beforehand and afterwards.

  • Technical Evaluation of consultant will be done on the basis of information / data given on these Forms / formats.

  • Pharmacopeia shall promptly notify in writing whether it accepts or rejects each such Target as a Screening Target.

Related to Screening Target

  • Screening Test means a drug or alcohol test which uses a method of analysis allowed by the Minnesota Drug and Alcohol Testing in the Workplace Act to be used for such purposes.

  • KPI Target means the acceptable performance level for a KPI as set out in each KPI;

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Soft Target means a target that will suffer minimum damage and cause minimum damage to the subject vehicle in the event of a collision.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Acquisition Target means any Person becoming a Subsidiary of the Company after the date hereof; any Person that is merged into or consolidated with the Company or any Subsidiary of the Company after the date hereof; or any Person with respect to which all or a substantial part of that Person’s assets are acquired by the Company or any Subsidiary of the Company after the date hereof.

  • ASAM criteria means the most current edition of the American Society of Addiction Medicine's published criteria for admission to treatment, continued services, and discharge.

  • Pivotal Clinical Trial means a pivotal human clinical trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.

  • Evaluation Criteria means the criteria set out under the clause 27 (Evaluation Process) of this Part C, which includes the Qualifying Criteria, Functional Criteria and Price and Preferential Points Assessment.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Development Milestone Event shall have the meaning set forth in Section 9.2(a).

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • TARGET 2 means the Trans-European Automated Real-time Gross Settlement Express Transfer payment system which utilizes a single shared platform and which was launched on November 19, 2007.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Target Population means persons with low incomes who have one or more disabilities, including mental illness, HIV or AIDS, substance abuse, or other chronic health condition, or individuals eligible for services provided pursuant to the Lanterman Developmental Disabilities Services Act (Division 4.5 (commencing with Section 4500) of the Welfare and Institutions Code) and may include, among other populations, adults, emancipated minors, families with children, elderly persons, young adults aging out of the foster care system, individuals exiting from institutional settings, veterans, and homeless people.

  • Phase IV Clinical Trial means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by BMS and that otherwise fit the foregoing definition.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Alternative nicotine product means any vaping product, whether or not it includes nicotine, including electronic smoking devices, that can be ingested into the body by chewing, smoking, absorbing, dissolving, inhaling, or by any other means. ‘Alternative nicotine product’ does not include:

  • DNA profile means a letter or number code which represents a set of identification characteristics of the non-coding part of an analysed human DNA sample, i.e. the particular molecular structure at the various DNA locations (loci);

  • Targets means pre-agreed values to be achieved at the end of the period in relation to the result indicators included under a specific objective;